Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 19, 2020 10:31 AM 7 min read

COVID Vaccine Logistics To Start As Sprint, Turn Into Marathon

by FreightWaves
Follow
FlipboardIcon version of the Flipboard logo

About 40 million doses of two leading COVID-19 vaccines could be available for nationwide distribution by the end of December, with similar amounts metered out each month afterward in a carefully synchronized manner to ensure all jurisdictions have a predictable supply, Operation Warp Speed officials said at a press conference Wednesday.

Vaccine candidates from Pfizer Inc. (NYSE:PFE) and Moderna (NASDAQ:MRNA) are expected to soon be authorized for emergency use by the Food and Drug Administration (FDA) after the companies this week said they were effective 95% of the time at preventing coronavirus symptoms.

The federal task force coordinating the nationwide immunization campaign has been working closely with jurisdictions to learn where they want vaccines to be shipped. Distribution is scheduled to begin within 24 hours of FDA authorization.

"The governors and the states will figure out the plan and we are ready to execute as we've been working on for six months, doing numerous tabletop exercises and now extending it into actual rehearsals of how to move the product from fill finish sites to distribution centers down to actual administration sites," Army Gen. Gus F. Perna, chief operations officer of Operation Warp Speed (OWS), said.

"After the initial push, we will begin a weekly cadence of delivery of vaccine … to ensure that we rapidly expand the availability to the entire country simultaneously," he said. A routine flow is important "so that jurisdictions can plan for it and develop execution of the administration in a routine method so that the population is well informed and they know when and where to get the vaccine." 

The stockpile will have 40 million doses by late December "and an equivalent, or slightly higher amount, on a monthly basis going forward to start immunizing the U.S. population," said Dr. Moncef Slaoui, chief adviser for OWS.

Forty million doses is enough to vaccinate about 20 million Americans, with the initial tranche targeted at frontline health care workers. After that, the Centers for Disease Control will prioritize distribution to nursing homes and other vulnerable groups and then vaccines will be allocated to states and other jurisdictions on a pro rata basis based on population.

In addition to the Pfizer and Moderna vaccines, two more vaccines are showing promise and could produce efficacy results by early January, Slaoui said.

OWS, led by the departments of Defense and Health and Human Services (HHS), has also procured ancillary supplies like needles, alcohol swabs and personal protective equipment that McKesson will assemble into kits to be paired up with vaccine supplies as they are distributed.

Last week, OWS reached nationwide agreements to allow administration of the vaccine by pharmacy chains and networks of independent pharmacies to cover more than 60% of the pharmacies across the country.

"The ultimate goal here is to make getting a COVID vaccine as convenient as getting a flu shot," HHS Secretary Alex Azar said.

Last month, the CDC published its interim vaccination program playbook, which state health departments used to develop comprehensive vaccine distribution plans. The CDC is currently reviewing the plans. 

The nation's 64 vaccination jurisdictions have to finish a few more steps to be ready for deliveries, according to Perna.

He urged health departments to submit their final lists of vaccine providers because OWS can only deliver to enrolled facilities, to sign data use agreements and keep practicing their administration plans. 

The data use agreements are important to help track every person who received a shot and ensure there aren't imbalances between supply and demand, especially since five of the six vaccine candidates require two doses three weeks apart. Providers will also use the information to notify people to return for their second dose. 

"We must be able to see who got their first dose, where they got it and what vaccine they received so we can ensure the same [delivery] for the second dose we are sending out," Perna said. "Our ability to track the uptake, the actual administration of the shot in an arm, is going to be essential to us being able to deliver a vaccine on a continuous basis."

Perna added that jurisdictions need to check and double-check their plans to make sure everything is in place as OWS ramps up real-world rehearsals to see how hospitals and other facilities receive, unload, store and administer the vaccines.

Once officials decide how to prioritize the initially limited doses, OWS will input the information into Tiberius to compute the quantities to be allocated to each jurisdiction, according to the Defense Department. Jurisdictions will work inside the platform to decide where every allocated does will go — from local doctors' offices to large medical centers — and distributors will then complete deliveries.

Perna said careful planning should eliminate the possibility for any vaccine to be wasted. The concern arises because of the need to maintain the drugs at the correct temperature for stability. The situation is particularly relevant for Pfizer's vaccine, which must be stored at minus 70 degrees Celsius (minus 94 Fahrenheit) or more.

The Pfizer thermal shipping container contains 975 doses, or 195 per tray. Once the vaccines thaw, they can be kept in normal refrigeration — minus 2 to minus 8 C —  for five days. 

The Moderna vaccine, which initially stores at minus 20 degrees C, comes in trays of 100 doses.

Pharmacies such as Walgreens and CVS "know how to break down and do small quantities. And we did detailed plans with them, working with the jurisdictions so that no vaccine is wasted so that when they go to immunize they have the right techniques and procedures to make sure that only the required doses are reduced to the right temperature for administration and that the others stay at the right temperature for stability," Perna said.

Click here for more FreightWaves/American Shipper stories by Eric Kulisch.

RELATED NEWS:

Biden transition freeze could harm COVID vaccine logistics, adviser says

Pfizer to bypass U.S. government system for COVID vaccine distribution

Pfizer plans ‘just-in-time' COVID-19 distribution in Canada

DoD planning ‘every logistical detail' of COVID vaccine distribution

FEMA launches 5-year supply chain plan for pandemic preparedness

Trump says military assets poised for COVID vaccine distribution

US Air Force could deploy freighters to fly truckloads of vaccines

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
BiotechNewsHealth CareGeneralCovid-19Freightvaccine
MRNA Logo
MRNAModerna Inc
$53.490.19%
Overview
PFE Logo
PFEPfizer Inc
$26.85-0.04%

Pfizer and Moderna have already started to stockpile vaccine doses because the U.S. government took the financial risk to invest upfront so companies could begin manufacturing and clinical trials before the drugs were determined to be effective. Under an agreement with the government, Pfizer will deliver 100 million doses with an option for an additional 500 million doses. OWS has provided about $2 billion in funding and operational support for development, manufacturing and delivery for similar quantities of the Moderna vaccine.

The federal government made development investments in five different vaccines, utilizing the military's logistics procurement skills to help manufacturers obtain all necessary materials and make sure there were no delays in production. It has upfront prepurchase agreements with six vaccines and a contract with McKesson Corp., a large health care distributor, to manage distribution to the country, with FedEx and UPS as the primary delivery subcontractors. Pfizer has an arrangement to ship directly from manufacturing sites to the designated administration sites.

On Monday, Pfizer announced it has launched a pilot delivery program for its experimental COVID vaccine with four states. The results will be used to refine its distribution plan as the program rolls out. Rhode Island, Texas, New Mexico and Tennessee were selected because of their differences in overall size, diversity of populations and immunization infrastructure, as well as their need to reach individuals in varied urban and rural settings, the company said. The four states will not receive vaccine doses earlier than other states or receive preferential consideration, it emphasized.

OWS developed a high-speed computer system that gives federal officials and states a view in one system of the entire COVID vaccine supply chain to support distribution and allocation. The Tiberius platform integrates data from various sources, including the CDC, U.S. Census, state health offices and HHS to provide a picture of manufacturing, clinical trials, logistics, allocation, state and territory planning, delivery and administration of both vaccine products and kits. 

MRNA Logo
MRNAModerna Inc
$53.490.19%
Overview
PFE Logo
PFEPfizer Inc
$26.85-0.04%
Comments
Loading...